Category 2 removal isnt legalization: what the May 12 analysis says One reason this topic surged again this week: a May 12 legal analysis summarized FDAs April 15 actions, including that FDA republished an interim 503A Bulks List and indicated its intent to remove certain peptides from its Category 2 list of bulk drug substances that raise significant safety concerns
These strategies are not supported by current German guidelines
Meanwhile, the type of space(s) people inhabit has been changing with ever-growing speed: this makes such hybridscapes crucial, but very difficult to understand, deconstruct and analyse as complex and multi-layered socio-technical systems, as far as their implications in terms of social interaction, dynamics of inclusion and exclusion and forms of differentiation and inequality are concerned (Kitchin, Cardullo, Di Feliciantonio 2019
Wilhelm I, Nyul-Toth A, Suciu M, Hermenean A, Krizbai IA